Pneumococcal conjugate second or third-dose vaccines (PCVc) in Tonga
Tonga: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 94.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Tonga, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Tonga is 94.0%, measured in 2025.
The figure is down 5.1% on the previous year.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Tonga peaked at 99.0% in 2023 and was at its lowest, 0.0%, in 2008.
That places Tonga 46th out of 194 countries with data for 2025, putting it in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Tonga, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 0.0% | — |
| 2019 | 0.0% | — |
| 2020 | 0.0% | — |
| 2021 | 67.0% | — |
| 2022 | 67.0% | +0.0% |
| 2023 | 99.0% | +47.8% |
| 2024 | 99.0% | +0.0% |
| 2025 | 94.0% | -5.1% |
Tonga compared with similar countries
- Tonga's 94.0% is above the median for upper middle income countries, which is 76.0%, 1.2× the median. (57 countries reporting)
- Tonga's 94.0% is above the median for East Asia & Pacific, which is 81.0%, 1.2× the median. (30 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 0.0% | 0.0% | 0.0% | 10 |
| 2020s | 71.0% | 0.0% | 99.0% | 6 |
Countries ranked near Tonga
More health data for Tonga
- Un projection of annual infant deaths, annual growth rate -33.33 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 2.33 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 834.5 deaths per 1,000 people (2090)
- Number of infants who die before age 1 2 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -1.42 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0535 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.36 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Tonga?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Tonga was 94.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Tonga?
- The highest recorded value was 99.0% in 2023.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Tonga?
- The lowest recorded value was 0.0% in 2008.
- How does Tonga rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Tonga ranks 46th out of 194 countries with data for 2025.
- Where does this Tonga data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).